Story perspectives

AstraZeneca Invests $15 Billion in China Expansion Plan

2/2/2026

50 5

Summary

Story summary

AstraZeneca announced a $15 billion investment in China through 2030 to expand manufacturing and research.
The investment coincides with UK Prime Minister Keir Starmer's visit to China, the first in eight years.
AstraZeneca will partner with CSPC Pharmaceuticals to expand its obesity portfolio, with an upfront payment of $1.2 billion.
The plan signals continued commitment to China, AstraZeneca's second-largest market, despite past regulatory challenges.

1 of 1

Story summary

AstraZeneca announced a $15 billion investment in China through 2030 to expand manufacturing and research.
The investment coincides with UK Prime Minister Keir Starmer's visit to China, the first in eight years.
AstraZeneca will partner with CSPC Pharmaceuticals to expand its obesity portfolio, with an upfront payment of $1.2 billion.
The plan signals continued commitment to China, AstraZeneca's second-largest market, despite past regulatory challenges.